Adjuvant immunotherapy conferred a 93% survival at 1 year for patients with resectable melanoma at the highest risk of relapse

  • The analysis captures the first survival data from the National Cancer Database (NCDB) since the FDA’s 2015 approval of ipilimumab (Yervoy) following curative intent surgery in stage III patients.
  • Survival data were available for the 4,094 patients diagnosed in 2015, of which 1,014 were treated with immunotherapy.
  • At 1 year, 93% of patients that received surgery plus immunotherapy were alive, as compared to 91% of those that received surgery alone.
  • At 2 years, 70% of stage IIIC patients who received surgery plus immunotherapy were alive compared to 59% of those who underwent surgery alone.

Click here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: JUL2020DC001